Home
Register
Log inThuốc trị Cô Vi
Page 1 of 1 • Share
Thuốc trị Cô Vi
by 8DonCo Thu May 27, 2021 8:38 am
FDA gives emergency use approval for Covid-19 antibody drug developed by Vir Biotechnology, GlaxoSmithKline
The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older.
The antibody drug, Sotrovimab, is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy, the health regulator said on Wednesday.
Sotrovimab belongs to a class of drugs called monoclonal antibodies, which mimic natural antibodies that the body generates to fight off infection.
The antibody treatment will be available for Covid-19 patients in the coming weeks, GSK and Vir said, adding that they plan to submit a marketing application to the FDA in the second half of 2021.
Similar Covid-19 therapies by Regeneron Pharmaceuticals and Eli Lilly have been authorized for emergency use in the United States.
The European Union’s drug regulator last week backed the use of Sotrovimab for Covid-19 patients who were at risk of severe disease and do not need supplemental oxygen.
- The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older.
- The antibody drug, Sotrovimab, is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy, the health regulator said on Wednesday.
The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate Covid-19 in people aged 12 years and older.
The antibody drug, Sotrovimab, is not authorized for patients who are hospitalized due to Covid-19 or require oxygen therapy, the health regulator said on Wednesday.
Sotrovimab belongs to a class of drugs called monoclonal antibodies, which mimic natural antibodies that the body generates to fight off infection.
The antibody treatment will be available for Covid-19 patients in the coming weeks, GSK and Vir said, adding that they plan to submit a marketing application to the FDA in the second half of 2021.
Similar Covid-19 therapies by Regeneron Pharmaceuticals and Eli Lilly have been authorized for emergency use in the United States.
The European Union’s drug regulator last week backed the use of Sotrovimab for Covid-19 patients who were at risk of severe disease and do not need supplemental oxygen.
_________________
8DonCo
Re: Thuốc trị Cô Vi
by TuTu Thu May 27, 2021 10:03 am
công nhạn things getting better ....cũng mừng .
ngày này năm trước rầu thuối ruột đi ....
ngày này năm trước rầu thuối ruột đi ....
TuTu
Similar topics» Xét rằng
» sầu riêng tiêm thuốc hay không tiêm thuốc
» Thuốc trị Cô Vi
» đã có thuốc trị Cô Vi ....
» Gà Ác hầm thuốc Bắc
» sầu riêng tiêm thuốc hay không tiêm thuốc
» Thuốc trị Cô Vi
» đã có thuốc trị Cô Vi ....
» Gà Ác hầm thuốc Bắc
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum